Literature DB >> 10626796

Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.

M J Riemenschneider1, R Büschges, M Wolter, J Reifenberger, J Boström, J A Kraus, U Schlegel, G Reifenberger.   

Abstract

We have previously reported on the amplification and overexpression of the MDM2 proto-oncogene in a subset of malignant gliomas without TP53 mutation (G. Reifenberger et al, Cancer Res., 53: 2736-2739, 1993). Here, we show that the MDM4 (MDMX) gene located on 1q32 is a further target for amplification in malignant gliomas. MDM4 codes for a Mdm2-related protein that can bind to p53 and inhibits p53-mediated transcriptional transactivation. We investigated a series of 208 gliomas (106 glioblastomas, 46 anaplastic gliomas, and 56 low-grade gliomas) and identified 5 tumors (4 glioblastomas and 1 anaplastic oligodendroglioma) with MDM4 amplification and overexpression. Several other genes from 1q32 were found to be coamplified with MDM4, such as GAC1 in five tumors, REN in four tumors, and RBBP5 in three tumors. Additional analyses revealed that the malignant gliomas with MDM4 amplification and overexpression carried neither mutations in conserved regions of the TP53 gene nor amplification of the MDM2 gene. Taken together, our data indicate that amplification and overexpression of MDM4 is a novel molecular mechanism by which a small fraction of human malignant gliomas escapes p53-dependent growth control.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626796

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  91 in total

Review 1.  Studying a complex tumor: potential and pitfalls.

Authors:  Siyuan Zheng; Milan G Chheda; Roel G W Verhaak
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2.

Authors:  Yetao Jin; Shelya X Zeng; Xiao-Xin Sun; Hunjoo Lee; Christine Blattner; Zhixiong Xiao; Hua Lu
Journal:  Mol Cell Biol       Date:  2007-12-17       Impact factor: 4.272

3.  Regulation of MDMX expression by mitogenic signaling.

Authors:  Daniele M Gilkes; Yu Pan; Domenico Coppola; Timothy Yeatman; Gary W Reuther; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2008-01-02       Impact factor: 4.272

4.  EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.

Authors:  Rossella Pellegrino; Diego F Calvisi; Olaf Neumann; Venkatesh Kolluru; Josephine Wesely; Xin Chen; Chunmei Wang; Torsten Wuestefeld; Sara Ladu; Nahla Elgohary; Justo Lorenzo Bermejo; Bernhard Radlwimmer; Martin Zörnig; Lars Zender; Frank Dombrowski; Matthias Evert; Peter Schirmacher; Thomas Longerich
Journal:  Hepatology       Date:  2014-03-27       Impact factor: 17.425

5.  Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation.

Authors:  Ewa D Micewicz; Shantanu Sharma; Alan J Waring; Hai T Luong; William H McBride; Piotr Ruchala
Journal:  Int J Pept Res Ther       Date:  2015-08-19       Impact factor: 1.931

Review 6.  New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents.

Authors:  Katerina Gurova
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

Review 7.  Two is better than one; toward a rational design of combinatorial therapy.

Authors:  Sheng-Hong Chen; Galit Lahav
Journal:  Curr Opin Struct Biol       Date:  2016-08-10       Impact factor: 6.809

Review 8.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

Review 9.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

10.  The p53-MDM2/MDMX axis - A chemotype perspective.

Authors:  Kareem Khoury; Grzegorz M Popowicz; Tad A Holak; Alexander Dömling
Journal:  Medchemcomm       Date:  2011       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.